BitMine Immersion Technologies (NYSEAM:BMNR) is navigating a turbulent period marked by over $6 billion in unrealized losses from its concentrated Ethereum holdings and the abrupt departure of its president. The company's aggressive crypto treasury strategy and governance decisions are now under the microscope.
A sharp correction in Bitcoin prices has left corporate giant MicroStrategy nursing over $1 billion in unrealized losses and triggered massive outflows from spot ETFs. Despite the sell-off, CEO Michael Saylor signals unwavering commitment, framing the downturn as a strategic buying opportunity.
Tesla maintained its Bitcoin position through a turbulent quarter, reporting significant unrealized losses as cryptocurrency markets slumped, even as its core automotive business outperformed expectations.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
As Virgin Galactic's stock hovers near historic lows, the market is grappling with a critical question: Is the pioneering space tourism company a deeply undervalued opportunity, or a speculative bet burdened by persistent losses and ambitious, yet unproven, timelines?
Nomura's digital asset arm, Laser Digital, reports quarterly losses leading to reduced crypto exposure, even as it aggressively pursues a US banking charter and global expansion, highlighting a dual-track strategy of short-term risk management and long-term infrastructure build-out.
In an exclusive interview, Robert F. Kennedy Jr. addresses the state of his relationship with cousin Caroline Kennedy following the death of her daughter, Tatiana Schlossberg, last December. The tragedy unfolds against a backdrop of deep political rifts within America's most storied political dynasty.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.
The global container shipping giant Ocean Network Express reported a net loss for its third fiscal quarter, citing soft demand and declining freight rates, particularly on key Asia-U.S. and Asia-Europe routes. The carrier anticipates a gradual recovery in the coming months.
GCL Global's fiscal first-half revenue nearly doubled after consolidating Ban Leong Technologies, yet the company reported a net loss as it absorbed acquisition costs. Management lowered full-year guidance, citing delays for two key game titles.
Indian e-commerce challenger Meesho reported a significant widening of its quarterly net loss to ₹4.91 billion, as a 44% surge in expenses outpaced strong revenue growth, marking a costly start to its life as a public company.
While Sligro Food Group (AMS:SLIGR) shares have seen a modest 11% rebound in recent months, long-term investors are nursing significant losses, with the stock down 46% over five years. This deep dive examines the disconnect between the company's path to profitability and its languishing share price.
SL Green Realty Corp. posted a significant net loss for 2025 despite rising revenues and robust leasing activity. The Manhattan office landlord confirmed a shift to quarterly dividends and is advancing major financing and asset sale plans, placing cash conservation and balance sheet flexibility at the forefront of its recovery strategy.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
Investors in lighting specialist FW Thorpe have seen a negative total shareholder return of 25% since 2021, starkly underperforming the broader market's gains. Despite steady revenue growth, the share price decline highlights a disconnect with company fundamentals.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
While Italtile's stock saw an 11% bump last month, a look at the past five years reveals a sobering picture for long-term investors, with total shareholder returns deep in negative territory even as company earnings grew.
